Vistagen Therapeutics, Inc.
VTGNNasdaq
$0.23
↓ -4.5%Jul 17 close · end-of-day
Price
1Y↓ -90.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.7M
Enterprise Value
-$36.7M
P/E
—
P/S
6.9
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.3M
Net Income (TTM)
-$69.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-5683.7%
Net Margin
-5491.3%
ROE
-196.2%
ROIC
—
Debt / Equity
—
Net Cash
$45.4M
Return 1Y
-91.0%
Company profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system. The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.
- CEO
- Shawn K. Singh
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- vistagen.com
Earnings
VTGN Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$464,000.00↓ -3193.3%
Diluted EPS-$0.37↓ -15.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | -$227,000.00 | $1.1M | $486,000.00 | $1.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$17.9M | -$47.8M | -$59.3M | -$33.0M | -$56.0M | -$72.1M |
| Net income | -$17.9M | -$47.8M | -$59.2M | -$29.4M | -$51.4M | -$69.7M |
| Diluted EPS | — | — | -$8.51 | -$1.52 | -$1.67 | -$1.83 |
| Operating cash flow | -$12.1M | -$45.3M | -$49.7M | -$25.8M | -$42.1M | -$66.4M |
| Free cash flow | -$12.3M | -$45.5M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1646.1% | -4308.3% | 26109.3% | -3103.5% | -11517.1% | -5683.7% |
| Net margin | -1646.1% | -4306.8% | 26100.4% | -2759.6% | -10579.8% | -5491.3% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84,000.00 | $183,000.00 | $234,000.00 | -$15,000.00 | $244,000.00 | $258,000.00 | $303,000.00 | $464,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.1M | -$14.2M | -$15.1M | -$14.5M | -$15.8M | -$20.1M | -$19.5M | -$16.7M |
| Net income | -$10.7M | -$13.0M | -$14.1M | -$13.6M | -$15.1M | -$19.4M | -$18.9M | -$16.3M |
| Diluted EPS | -$0.35 | -$0.42 | -$0.46 | -$0.44 | -$0.47 | -$0.54 | -$0.45 | -$0.37 |
| Operating cash flow | -$10.9M | -$10.9M | -$10.3M | -$10.1M | -$18.8M | -$13.8M | -$17.6M | -$16.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -14441.7% | -7774.3% | -6461.5% | 96633.3% | -6477.0% | -7772.5% | -6450.8% | -3604.1% |
| Net margin | -12777.4% | -7082.5% | -6020.9% | 90900.0% | -6186.5% | -7526.0% | -6237.3% | -3507.3% |
Company news
Jun 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.